Mather Group, Llc. Crinetics Pharmaceuticals, Inc. Transaction History
Mather Group, Llc.
- $8.58 Billion
- Q1 2025
A detailed history of Mather Group, Llc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Mather Group, Llc. holds 70 shares of CRNX stock, worth $2,267. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70Holding current value
$2,267% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
253Shares Held
82.4MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$294 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$202 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$199 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$175 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.29MShares$139 Million10.24% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.74B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...